Old Web
English
Sign In
Acemap
>
Paper
>
1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors
1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors
2020
F. Morschhauser
Pamela McKay
Gilles Salles
Silvia Stacchiotti
Gary K. Schwartz
H. Tilly
M. G. Zauderer
D. A. Fennell
R. L. Jones
Patrick Schöffski
Tycel J. Phillips
Aristeidis Chaidos
Victor Villalobos
G. D. Demetri
Gregory M. Cote
L. Sierra
Jay Yang
P. Slatcher
S. Agarwal
Mrinal M. Gounder
Keywords:
Tazemetostat
Oncology
adult patients
Internal medicine
Medicine
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]
map